Your browser doesn't support javascript.
loading
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.
Pancera, Marie; Lai, Yen-Ting; Bylund, Tatsiana; Druz, Aliaksandr; Narpala, Sandeep; O'Dell, Sijy; Schön, Arne; Bailer, Robert T; Chuang, Gwo-Yu; Geng, Hui; Louder, Mark K; Rawi, Reda; Soumana, Djade I; Finzi, Andrés; Herschhorn, Alon; Madani, Navid; Sodroski, Joseph; Freire, Ernesto; Langley, David R; Mascola, John R; McDermott, Adrian B; Kwong, Peter D.
Afiliación
  • Pancera M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Lai YT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Bylund T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Druz A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Narpala S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • O'Dell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Schön A; Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Bailer RT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Chuang GY; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Geng H; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Louder MK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Rawi R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Soumana DI; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Finzi A; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, Quebec, Canada.
  • Herschhorn A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Madani N; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Sodroski J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Freire E; Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Langley DR; Computer Assisted Drug Design, Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Nat Chem Biol ; 13(10): 1115-1122, 2017 Oct.
Article en En | MEDLINE | ID: mdl-28825711
The HIV-1 envelope (Env) spike is a conformational machine that transitions between prefusion (closed, CD4- and CCR5-bound) and postfusion states to facilitate HIV-1 entry into cells. Although the prefusion closed conformation is a potential target for inhibition, development of small-molecule leads has been stymied by difficulties in obtaining structural information. Here, we report crystal structures at 3.8-Å resolution of an HIV-1-Env trimer with BMS-378806 and a derivative BMS-626529 for which a prodrug version is currently in Phase III clinical trials. Both lead candidates recognized an induced binding pocket that was mostly excluded from solvent and comprised of Env elements from a conserved helix and the ß20-21 hairpin. In both structures, the ß20-21 region assumed a conformation distinct from prefusion-closed and CD4-bound states. Together with biophysical and antigenicity characterizations, the structures illuminate the allosteric and competitive mechanisms by which these small-molecule leads inhibit CD4-induced structural changes in Env.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperazinas / Triazoles / Proteína gp41 de Envoltorio del VIH / Proteína gp120 de Envoltorio del VIH / Internalización del Virus / Bibliotecas de Moléculas Pequeñas Idioma: En Revista: Nat Chem Biol Asunto de la revista: BIOLOGIA / QUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperazinas / Triazoles / Proteína gp41 de Envoltorio del VIH / Proteína gp120 de Envoltorio del VIH / Internalización del Virus / Bibliotecas de Moléculas Pequeñas Idioma: En Revista: Nat Chem Biol Asunto de la revista: BIOLOGIA / QUIMICA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
...